Comparison of Care Cascade Outcome Measures for Hepatitis C Among Insured US Adults
-
By
-
Hasan Symum
-
Brooke Hoots
-
Harvey W. Kaufman
-
William A. Meyer
-
Ademola Osinubi
-
Andrew Kress
-
William W. Thompson
-
Carolyn Wester
-
July 6, 2026
-
Clinical Scorecard: Evaluation of Hepatitis C Care Cascade Outcomes Among Insured Adults in the United States
At a Glance
| Category | Detail |
|---|
| Condition | Hepatitis C Virus (HCV) |
| Key Mechanisms | Direct-acting antivirals (DAAs) cure most (>95%) cases. |
| Target Population | Insured adults aged ≥18 years with HCV infection. |
| Care Setting | Health care systems with access to laboratory and pharmacy data. |
Key Highlights
- 39.9% of individuals with initial infection achieved viral clearance.
- 35.7% initiated treatment within 360 days of initial infection.
- 73.2% of those who initiated treatment had a subsequent HCV RNA-negative result.
Guideline-Based Recommendations
Diagnosis
- Use laboratory data to document viral clearance.
- Monitor HCV RNA testing post-treatment.
Management
- DAAs are effective for treating HCV with a high cure rate.
Monitoring & Follow-up
- Follow-up HCV RNA testing is essential to assess viral clearance.
Risks
- Underestimation of viral clearance due to lack of follow-up testing.
Patient & Prescribing Data
Adults with documented HCV infection and continuous insurance enrollment.
91.0% of patients prescribed DAAs likely achieved treatment-induced viral clearance.
Clinical Best Practices
- Integrate laboratory and pharmacy data for accurate outcome assessment.
- Encourage follow-up RNA testing after treatment initiation.
Related Resources & Content
